0001640455-20-000116.txt : 20200916
0001640455-20-000116.hdr.sgml : 20200916
20200916184343
ACCESSION NUMBER: 0001640455-20-000116
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200916
DATE AS OF CHANGE: 20200916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duncan Barbara Gayle
CENTRAL INDEX KEY: 0001353128
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 201179704
MAIL ADDRESS:
STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC.
STREET 2: 18 DESBROSSES STREET
CITY: NEW YORK
STATE: NY
ZIP: 10013
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_160029620899164.xml
FORM 4
X0306
4
2020-09-15
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001353128
Duncan Barbara Gayle
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2020-09-15
4
M
0
10000
4.21
A
10000
D
Common Stock
2020-09-15
4
S
0
5000
9.50
D
5000
D
Common Stock
2020-09-15
4
S
0
5000
10.50
D
0
D
Stock Option (Right to Buy)
4.21
2020-09-15
4
M
0
10000
0
D
2026-05-09
Common Stock
10000.0
34271
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2019. The Reporting Person exercised no discretion with respect to these transactions.
The option shares vested and became exercisable in 16 quarterly installments from May 10, 2016.
/s/ Kim C. Drapkin, Attorney-in-Fact
2020-09-16